Literature DB >> 7606858

European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7606858      PMCID： PMC1553550          DOI： 10.1111/j.1365-2249.1995.tb06161.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  19 in total

1.  Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies.

Authors:  C D Pusey; A J Rees; D J Evans; D K Peters; C M Lockwood
Journal:  Kidney Int       Date:  1991-10       Impact factor: 10.612

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?

Authors:  R A DeRemee
Journal:  Arthritis Rheum       Date:  1988-08

4.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network.

Authors:  R J Falk; S Hogan; T S Carey; J C Jennette
Journal:  Ann Intern Med       Date:  1990-11-01       Impact factor: 25.391

5.  Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide.

Authors:  G S Hoffman; R Y Leavitt; T A Fleisher; J R Minor; A S Fauci
Journal:  Am J Med       Date:  1990-10       Impact factor: 4.965

6.  Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis.

Authors:  W K Bolton; B C Sturgill
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

7.  The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization.

Authors:  E C Hagen; K Andrassy; E Chernok; M R Daha; G Gaskin; W Gross; P Lesavre; J Lüdemann; C D Pusey; N Rasmussen
Journal:  J Immunol Methods       Date:  1993-02-26       Impact factor: 2.303

8.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

9.  Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years.

Authors:  L Guillevin; F Lhote; B Jarrousse; O Fain
Journal:  Ann Med Interne (Paris)       Date:  1992

10.  The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate.

Authors:  G S Hoffman; R Y Leavitt; G S Kerr; A S Fauci
Journal:  Arthritis Rheum       Date:  1992-11
View more
  15 in total

Review 1.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 3.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 4.  Vasculitis for the internist: focus on ANCA-associated vasculitis.

Authors:  Benjamin Chaigne; Loïc Guillevin
Journal:  Intern Emerg Med       Date:  2017-06-16       Impact factor: 3.397

5.  Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience.

Authors:  Pavel I Novikov; Sergey V Moiseev; Ekaterina I Kuznetsova; Eugenia N Semenkova; Nikolay A Mukhin
Journal:  Rheumatol Int       Date:  2014-10-26       Impact factor: 2.631

6.  Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis.

Authors:  Neil Basu; Gareth T Jones; Nick Fluck; Alan G MacDonald; Dong Pang; Paula Dospinescu; David M Reid; Gary J Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2010-04-17       Impact factor: 7.580

7.  Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study.

Authors:  Claudius Speer; Christine Altenmüller-Walther; Jan Splitthoff; Christian Nusshag; Florian Kälble; Paula Reichel; Christian Morath; Martin Zeier; Raoul Bergner; Matthias Schaier
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

8.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 9.  Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.

Authors:  Ágnes Haris; Szilveszter Dolgos; Kálmán Polner
Journal:  Int Urol Nephrol       Date:  2016-09-26       Impact factor: 2.370

Review 10.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.